Novel Associations of Empagliflozin on the Gut Microbiome and Metabolome in Type 2 Diabetes
- 8 June 2022
- journal article
- editorial
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (10) , e4246-e4247
Abstract
Ashani Lecamwasam, Elif I Ekinci; Novel associations of empagliflozin on the gut microbiome and metabolome in type 2 diabetes, The Journal of Clinical EndocrinoKeywords
This publication has 9 references indexed in Scilit:
- Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2022
- Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized TrialDiabetes Care, 2021
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialThe Lancet Diabetes & Endocrinology, 2021
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular diseaseNature Communications, 2020
- Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetesDiabetes & Metabolism, 2020
- Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational studyDiabetes Research and Clinical Practice, 2019
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?Diabetes, Obesity and Metabolism, 2018
- Richness and ecosystem development across faecal snapshots of the gut microbiotaNature Microbiology, 2018
- Microbiome-wide association studies link dynamic microbial consortia to diseaseNature, 2016